Polish Children's Hospital Splits Blood-Derived Medicine Contracts Among Four Pharmaceutical Suppliers

Standfirst:

A public children's hospital in Bydgoszcz has awarded four contracts for the year long supply of immunoglobulins and albumin to Takeda Pharma, URTICA, NOBIPHARM and CSL Behring. The procurement highlights how hospitals divide critical blood derived medicines into separate lots to protect supply continuity while allowing specialist pharmaceutical suppliers to compete for individual product categories.

For children living with immune disorders, neurological diseases and other serious medical conditions, access to blood derived medicines is not simply a matter of hospital inventory. Treatment can depend on a reliable supply of specialised products that are difficult to manufacture, tightly regulated and vulnerable to changes in global plasma availability.

That makes a new procurement decision in Bydgoszcz more significant than its four supply contracts might initially suggest. The Wojewódzki Szpital Dziecięcy im. J. Brudzińskiego, a specialist children's hospital in northern Poland, has selected four pharmaceutical suppliers to provide different categories of immunoglobulins and albumin over a 12 month period.

Rather than relying on a single company, the hospital divided the procurement into four lots and awarded each product category separately. Takeda Pharma secured the largest value lot, while URTICA, NOBIPHARM and CSL Behring won contracts covering other concentrations of immunoglobulins and albumin.

Why This Contract Matters

Immunoglobulins are medicines produced from donated human plasma. They contain antibodies that help the immune system fight infection and are used to treat a range of immune deficiencies, autoimmune disorders and neurological conditions. For some patients, regular treatment is essential to prevent serious illness or control disease progression.

Albumin is another plasma derived product. It is used in clinical situations where patients need support in maintaining blood volume and fluid balance, including some cases involving major surgery, severe illness or critical care.

Unlike many conventional medicines, plasma derived therapies depend on a complex international supply chain that begins with human plasma collection and continues through lengthy manufacturing, purification, safety testing and regulatory processes. Hospitals therefore need procurement arrangements that provide both competitive pricing and dependable access to treatment.

For the Bydgoszcz children's hospital, dividing the requirement into four lots allowed suppliers to compete for the specific product categories they were equipped to deliver. The result is a diversified supplier base rather than dependence on one company for the entire requirement.

Contract Timeline

• Previous Contract Notice: TED Notice 282110-2026
• Contract Signed for Lot 1: 19 June 2026
• Contract Signed for Lot 2: 23 June 2026
• Contracts Signed for Lots 3 and 4: 19 June 2026
• Supply Period: 1 July 2026 to 30 June 2027
• Contract Award Notice Published: 15 July 2026

Contract Overview

The procurement covers successive deliveries of blood derived medicinal products to the Wojewódzki Szpital Dziecięcy im. J. Brudzińskiego in Bydgoszcz. Supplies will be delivered according to the hospital's requirements during the contract period rather than necessarily being provided in a single shipment.

The requirement was divided into four lots: 10% immunoglobulins, two separate categories of 5% immunoglobulins and 20% albumin. All four lots resulted in contract awards.

The hospital also retained an option to increase the quantity supplied under each contract by up to 10% of the value of the corresponding base order. This gives the buyer flexibility to respond to actual treatment demand without launching a new procurement procedure.

Key Contract Details

Contracting Authority	Wojewódzki Szpital Dziecięcy im. J. Brudzińskiego w Bydgoszczy
Country	Poland
Location	Bydgoszcz, Kujawsko Pomorskie
Contract Type	Supplies
Procurement Procedure	Open procedure
Number of Lots	4
Successful Suppliers	Takeda Pharma Sp. z o.o.; URTICA Sp. z o.o.; NOBIPHARM Sp. z o.o.; CSL BEHRING Sp. z o.o.
Contract Period	1 July 2026 to 30 June 2027
Award Criterion	Price – 100%
Main CPV Code	33651520 – Immunoglobulins
Additional CPV Code	33621400 – Blood substitutes and perfusion solutions
EU Procurement Directive	Directive 2014/24/EU
TED Notice ID	488806-2026

Lot by Lot Award Results

Lot	Product Category	Winning Supplier	Reported Tender Value	Tenders Received
Lot 1	10% Immunoglobulins	Takeda Pharma Sp. z o.o.	PLN 24,744,500	2
Lot 2	5% Immunoglobulins I	URTICA Sp. z o.o.	PLN 944,058.50	2
Lot 3	5% Immunoglobulins II	NOBIPHARM Sp. z o.o.	PLN 88,000	1
Lot 4	20% Albumin	CSL BEHRING Sp. z o.o.	PLN 16,280	5

Note: The values above are reproduced as reported in the TED award notice. Some reported tender values appear inconsistent with the separate admissible tender ranges stated in the notice and should therefore be interpreted with caution.

Project Scope

The contracts provide for successive deliveries of four categories of plasma derived medicines during the 12 month supply period.

• Lot 1: Supply of 10% immunoglobulin products.
• Lot 2: Supply of the first category of 5% immunoglobulin products.
• Lot 3: Supply of the second category of 5% immunoglobulin products.
• Lot 4: Supply of 20% albumin products.

The 10% immunoglobulin products procured under Lot 1 may be used within Poland's National Health Fund reimbursement programme for the treatment of neurological diseases with immunoglobulins. This connects the procurement directly to the continuity of publicly funded specialist treatment.

The contracts also include a purchasing option of up to 10% above the value of each base order. The hospital may use this option in full or in part according to actual demand, without requiring a separate contract amendment.

About the Contracting Authority

Wojewódzki Szpital Dziecięcy im. J. Brudzińskiego w Bydgoszczy is a public children's hospital serving Bydgoszcz and the wider Kujawsko Pomorskie region. As a specialist paediatric healthcare institution, it provides medical services to children requiring hospital treatment, diagnostics and specialist care.

The hospital conducted the procurement as a body governed by public law under Poland's public procurement framework. By arranging scheduled deliveries across a full year, the hospital aims to maintain access to essential blood derived medicines while managing pharmaceutical inventory according to clinical demand.

About the Organisations Involved

Takeda Pharma Sp. z o.o. – Winner of Lot 1

Takeda Pharma Sp. z o.o. won the contract for 10% immunoglobulins, the largest product category in the procurement by reported award value. The company is the Polish operation of Takeda, an international biopharmaceutical group with activities across specialised medicines, including plasma derived therapies.

Two tenders were received for the lot. Takeda's offer was ranked first under the procurement's price only evaluation model. The contract was concluded on 19 June 2026 and does not involve subcontracting.

URTICA Sp. z o.o. – Winner of Lot 2

URTICA Sp. z o.o. secured the first lot covering 5% immunoglobulins. The Wrocław based company operates in pharmaceutical distribution and supplies medicines to healthcare institutions across Poland.

The lot attracted two tenders, including one from a small or medium sized enterprise. URTICA's offer ranked first and the contract was concluded on 23 June 2026. No subcontracting was declared.

NOBIPHARM Sp. z o.o. – Winner of Lot 3

NOBIPHARM Sp. z o.o. won the second category of 5% immunoglobulins. The Warsaw based pharmaceutical supplier was identified in the notice as a small enterprise.

Only one tender was received for this lot, making NOBIPHARM the sole bidder. The contract was concluded on 19 June 2026, with no subcontracting planned.

CSL BEHRING Sp. z o.o. – Winner of Lot 4

CSL BEHRING Sp. z o.o. secured the contract for 20% albumin. CSL Behring specialises in plasma derived and other therapies used in the treatment of rare and serious diseases.

Lot 4 attracted five tenders, the highest level of competition among the four product categories. CSL Behring's offer was ranked first and the contract was concluded on 19 June 2026. The supplier did not declare any subcontracting.

Krajowa Izba Odwoławcza – Procurement Review Body

Krajowa Izba Odwoławcza, Poland's National Appeals Chamber, is the review authority for the procurement. It provides the formal mechanism through which suppliers may challenge procurement decisions where they believe public procurement rules have been breached.

Procurement Analysis

The hospital used an open procedure, allowing qualified suppliers to submit bids for one or more of the four lots. The procurement was not accelerated and all tenders were submitted electronically.

Price carried a weighting of 100% across all four lots. This means the hospital selected the lowest priced admissible offer after confirming that the bidder met the required legal, technical and procurement conditions.

The procurement also used Poland's so called reverse procedure. Under this approach, the contracting authority first evaluates and ranks the offers and then conducts detailed eligibility checks on the highest ranked supplier. The method can reduce administrative work because full qualification checks do not have to be completed for every bidder at the initial evaluation stage.

Competition varied considerably by product category. The 20% albumin lot attracted five tenders, while the second 5% immunoglobulin lot received only one. This difference suggests that supplier availability and competitive intensity are not uniform across the plasma derived medicines market.

Additional Procurement Facts

• Legal Basis: Directive 2014/24/EU
• Nature of Contract: Supplies
• Procedure: Open procedure
• Accelerated Procedure: No
• Award Criterion: Price – 100%
• Framework Agreement: No
• Dynamic Purchasing System: No
• Government Procurement Agreement: Covered
• EU Funding: No EU funding involved
• Contract Option: Up to 10% additional supply value for each lot
• Subcontracting: Not declared by any of the four successful suppliers
• Review Authority: Krajowa Izba Odwoławcza

Market & Industry Perspective

The market for plasma derived medicines operates under conditions that differ from those of conventional pharmaceutical manufacturing. Production depends on the availability of donated human plasma, while manufacturing and safety controls can take several months. This limits how quickly supply can respond when demand rises.

The varying number of bids across the four lots offers a useful view of competition within individual product categories. Albumin attracted five offers, suggesting a broader competitive field, while one immunoglobulin lot received only a single bid. For public healthcare buyers, limited competition in specific formulations may increase the importance of early procurement planning and supplier engagement.

Future procurement opportunities are likely to emerge as hospitals renew annual medicine supply contracts, adjust quantities to changing treatment demand and use optional purchasing provisions where consumption exceeds initial forecasts.

Economic Significance

The largest reported award went to Takeda Pharma for the supply of 10% immunoglobulins. This reflects the importance of concentrated immunoglobulin therapies within specialist treatment and Poland's publicly funded neurological treatment programmes.

The economic significance of the procurement extends beyond the individual award values. Reliable access to these medicines can help hospitals maintain treatment schedules, reduce the operational risk associated with supply interruptions and provide greater predictability in pharmaceutical expenditure.

The 10% option attached to every lot also creates controlled financial flexibility. Rather than committing immediately to maximum quantities, the hospital can increase purchases if clinical demand requires additional supply.

Future Procurement Opportunities

The contracts are scheduled to end on 30 June 2027, creating a potential future procurement cycle before the current supply period expires. Suppliers active in immunoglobulins, albumin and plasma derived therapies should monitor procurement activity from the Bydgoszcz children's hospital and other Polish healthcare institutions during the first half of 2027.

Additional opportunities may arise earlier if treatment demand exceeds the hospital's original forecasts. However, the existing contracts allow the hospital to increase purchases by up to 10%, meaning some additional demand may be met through the current suppliers rather than through a new tender.

Future competitions may also reflect changes in medicine availability, reimbursement programmes, clinical demand and pricing across the European plasma products market.

Opportunities for Suppliers

Manufacturers and authorised pharmaceutical distributors can use similar hospital procurements to build a pipeline of recurring public sector opportunities. The lot based structure allows suppliers to compete for individual product categories without needing to provide the hospital's entire portfolio of blood derived medicines.

Companies seeking future opportunities should maintain the regulatory approvals, distribution capacity and product availability needed to support uninterrupted hospital supply. Monitoring annual contract expiry dates may also help suppliers identify upcoming tenders before formal notices are published.

The participation of both large pharmaceutical companies and a small enterprise among the successful bidders shows that specialised suppliers can compete effectively when contracts are divided into focused product lots.

What Businesses Should Watch

• Renewal procurement before the current contracts expire on 30 June 2027.
• Future immunoglobulin and albumin tenders from Polish hospitals and regional healthcare authorities.
• Changes in demand under Poland's publicly funded immunoglobulin treatment programmes.
• Whether hospitals increase contract quantities through purchasing options.
• Competition levels for specialised immunoglobulin concentrations where few suppliers submit bids.
• Changes in European plasma availability and their effect on medicine pricing and procurement strategy.

PolandTenders.com Procurement Intelligence

This award reflects a broader procurement strategy in which healthcare buyers divide specialised pharmaceutical requirements into product specific lots rather than placing the entire supply obligation with one company. The approach can widen participation, improve price competition and reduce dependence on a single supplier.

The tender results also show that the blood derived medicines market cannot be treated as one uniform category. Competition ranged from one tender for Lot 3 to five tenders for Lot 4. For buyers, this means procurement strategy may need to be adapted to the supplier depth available for each medicine and concentration.

For suppliers, the opportunity is not limited to major national medicine contracts. Annual hospital level procurements can provide recurring business, particularly for companies able to demonstrate reliable product availability and fulfil scheduled deliveries over extended periods.

The use of a 10% purchasing option is also strategically important. It gives the hospital a buffer against changes in patient demand while allowing successful suppliers to capture additional orders during the contract period. Future tenders may increasingly use similar flexibility where medicine consumption is difficult to forecast precisely.

Supplier Takeaways

• Track annual immunoglobulin and albumin supply contracts across Poland's public healthcare system.
• Monitor contract expiry dates well before renewal notices are published.
• Prepare for price led competitions where technical compliance is mandatory but price determines final ranking.
• Evaluate opportunities lot by lot, as competition differs significantly between product categories.
• Maintain sufficient inventory and distribution capacity to support successive hospital deliveries.
• Consider the additional commercial potential created by quantity options in awarded contracts.

Key Takeaways

• A public children's hospital in Bydgoszcz awarded four contracts for immunoglobulins and albumin supplies.
• Takeda Pharma, URTICA, NOBIPHARM and CSL Behring each won one product lot.
• The contracts cover supplies from 1 July 2026 to 30 June 2027.
• The procurement was conducted through an open procedure under Directive 2014/24/EU.
• Price accounted for 100% of the award evaluation.
• Competition ranged from one tender for a 5% immunoglobulin lot to five tenders for the albumin lot.
• Each contract includes an option allowing the hospital to increase supply by up to 10% of the base order value.
• No EU funding, framework agreement or dynamic purchasing system was involved.

Conclusion

Behind every hospital medicine contract is a practical question: will the required treatment be available when a patient needs it? For a children's hospital managing specialised and potentially life sustaining therapies, supply continuity is as important as procurement price.

By dividing its requirement among Takeda Pharma, URTICA, NOBIPHARM and CSL Behring, the Bydgoszcz hospital has created a multi supplier structure covering four categories of immunoglobulins and albumin. The awards also reveal a market with uneven competition, where some products attract several suppliers while others depend on a much narrower field.

For pharmaceutical companies and distributors, the procurement points to a recurring opportunity in Poland's public healthcare market: specialised medicine contracts that reward regulatory readiness, reliable distribution and the ability to compete within precisely defined product categories.

Frequently Asked Questions

What medicines are covered by the contracts?

The procurement covers 10% immunoglobulins, two categories of 5% immunoglobulins and 20% albumin.

Which companies won the contracts?

Takeda Pharma Sp. z o.o. won Lot 1, URTICA Sp. z o.o. won Lot 2, NOBIPHARM Sp. z o.o. won Lot 3 and CSL BEHRING Sp. z o.o. won Lot 4.

What are immunoglobulins?

Immunoglobulins are antibody based medicines produced from donated human plasma. They are used to treat immune deficiencies, autoimmune conditions and certain neurological diseases.

What is albumin used for?

Albumin is a plasma derived protein used in clinical care to help maintain blood volume and fluid balance in certain serious medical conditions.

How long will the contracts run?

The supply period runs from 1 July 2026 to 30 June 2027.

How were the winning suppliers selected?

The contracts were awarded through an open procedure. Price represented 100% of the award evaluation after suppliers met the procurement's eligibility and technical requirements.

How many tenders were received?

Lots 1 and 2 each received two tenders, Lot 3 received one tender and Lot 4 received five tenders.

Can the hospital purchase additional quantities?

Yes. Each contract includes an option allowing the hospital to increase purchases by up to 10% of the value of the corresponding base order.

Was the procurement financed by the European Union?

No. The TED notice states that the procurement is not financed with EU funds.

Source: Tenders Electronic Daily (TED), Contract Award Notice 488806-2026, published on 15 July 2026.